Microfluidic Device for Patient-Centric Multiplexed Assays with Readout in Centralized Laboratories
Hauser et al.
The finding, in our words
The authors developed a capillary microfluidic device that captures multiple blood biomarkers at collection and dries them on-chip, enabling safe shipment to centralised laboratories for multiplexed analysis. This patient-centric approach could support remote health monitoring and decentralised trials.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Targeted proteomic evaluation of a novel finger-prick dried plasma device demonstrated strong quantitative correlation with conventional plasma (R = 0.99) and precision under 10% CV for 80% of quantified peptides across healthy donors. Quantified targets also remained stable during room temperature storage for up to 232 days, supporting its use for decentralised biomarker monitoring.
Capillary dried blood spots, after haematocrit-dependent conversion, showed good agreement with plasma for 25-hydroxyvitamin D quantification, with 90 per cent of results within 20 per cent of plasma and substantial to almost perfect agreement in status classification, supporting reliable home self-collection for large-scale vitamin D monitoring.
The study found that capillary dried plasma spots correlated strongly with venous plasma for detecting the Alzheimer's disease biomarker p-tau217. This suggests that microsampling offers a viable, minimally invasive alternative to venipuncture for screening and monitoring Alzheimer's disease pathology.
The study found that although participants preferred patient-centric microsampling devices for home use, the agreement with venous plasma for measuring CRP and cytokines was inconsistent, indicating that further validation is required before these methods replace standard venipuncture.
A machine learning model called Remote Control was trained on 2685 blood samples to predict change due to instability, enabling accurate calibration of results to approximate the time zero value at collection. With calibration, unprocessed whole blood could be transported for up to 9 days under ambient conditions and temperatures between 3.4 and 47.4 degrees Celsius, achieving agreement with CLIA TEa between 98.1 and 100 per cent and expanding the catalog of tests available for at-home collection.